Broad spectrum anticonvulsant activity of BW534U87: Possible role of an adenosine-dependent mechanism

Pharmacology Biochemistry and Behavior

Volumn 74, Issue 1, 2002, Pages 111-118

  Southam, Eric ^a,c   Stratton, Sharon C ^a   Sargent, Rebecca S ^a   Brackenborough, Kim T ^a   Duffy, Claire ^a   Hagan, Russell M ^a   Pratt, Gerard D ^a   Jones, Stacey A ^b   Morgan, Philip F ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c Psychiatry Centre of Excellence for Drug Discovery   (United Kingdom)

Author keywords

Adenosine; Adenosine deaminase; Anticonvulsant; BW534U87; EHNA; EL mouse; Electrical kindling; Maximal electroshock seizure; Mouse; PTZ; Rat; Seizure models

Indexed keywords

1 [(2,6 DIFLUOROPHENYL)METHYL] 1H 1,2,3 TRIAZOLO[4,5 C]PYRIDIN 4 AMINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 (2 HYDROXY 3 NONYL)ADENINE; ADENOSINE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE DEAMINASE; ADENOSINE DEAMINASE INHIBITOR; ANTICONVULSIVE AGENT; BW 534U87; PENTETRAZOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN HOMOGENATE; CONTROLLED STUDY; DEAMINATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; ELECTRIC SHOCK; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; KINDLING; LATENT PERIOD; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE; VESTIBULAR STIMULATION;

ADENINE; ADENOSINE; ADENOSINE DEAMINASE; AMYGDALA; ANIMALS; ANTICONVULSANTS; CONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; ENZYME INHIBITORS; FEMALE; KINDLING, NEUROLOGIC; MALE; MICE; PENTYLENETETRAZOLE; RATS; RATS, WISTAR; RECEPTORS, PURINERGIC P1; SEIZURES; TRIAZOLES; XANTHINES;

ANIMALIA; RODENTIA;

EID: 0036887623     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(02)00956-5     Document Type: Article

References (36)

1. Abdul-Ghani A.-S., Attwell P.J.E., Bradford H.F. The protective effect of 2-chloroadenosine against the development of amygdala kindling and on amygdala-kindled seizures. Eur. J. Pharmacol. 326:1997;7-14.
2. A receptor agonists on pentylenetetrazole-induced convulsions in the rat. Eur. J. Pharmacol. 294:1995;383-389.
3. Ault B., Olney M.A., Joyner J.L., Boyer C.E., Notrica M.A., Soroko F.E., Wang C.M. Pro-convulsant actions of theophylline and caffeine in the hippocampus: implications for the management of temporal lobe epilepsy. Brain Res. 426:1987;93-102.
4. Berman R.F., Fredholm B.B., Aden U., O'Connor W.T. Evidence for increased dorsal hippocampal adenosine release and metabolism during pharmacologically induced seizures in rats. Brain Res. 872:2000;44-53.
5. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
6. Brundege J.M., Dunwiddie T.V. Role of adenosine as a modulator of synaptic activity in the central nervous system. Adv. Pharmacol. 39:1997;353-391.
7. 6-cyclopentyladenosine, an adenosine A1 receptor agonist, reduce GABAergic transmission in different areas of the mouse brain. J. Pharmacol. Exp. Ther. 267:1993;844-851.
8. Dragunow M. Purinergic mechanisms in epilepsy. Prog. Neurobiol. 31:1988;85-108.
9. + channels. Br. J. Pharmacol. 128:1999;1011-1020.
10. During M.J., Spencer D.D. Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann. Neurol. 32:1992;618-624.
11. Eldridge F.L., Paydarfar D., Scott S.C., Dowell R.T. Role of endogenous adenosine in recurrent generalized seizures. Exp. Neurol. 103:1989;179-185.
12. Geiger J.D., Nagy J.I. Distribution of adenosine deaminase activity in rat brain and spinal cord. J. Neurosci. 6:1986;2707-2714.
13. Goddard G.V., McIntyre D.C., Leech C.K. A permanent change in brain function resulting from daily electrical stimulation. Exp. Neurol. 25:1969;295-330.
14. Guisti G., Galanti B. Adenosine deaminase, colorimetric method. Bergmeyer H.U., Bergmeyer J., Grassl M. Methods of enzymatic analysis. Enzymes 2: esterases, glycosidases, lyases, ligases. vol. IV:1984;315-323 Verlag Chemie, Weinheim.
15. Haleen S.J., Steffen R.P., Hamilton H.W. PD116,948, a highly selective A1 receptor antagonist. Life Sci. 40:1987;551-561.
16. Kelley J.L., Koble C.S., Davis R.G., McLean E.W., Soroko F.E., Cooper B.R. 1-(Fluorobenzyl)-4-amino-1H-1,2,3-triazolo[4,5-c]pyridines: synthesis and anticonvulsant activity. J. Med. Chem. 38:1995;4131-4134.
17. Kimball A.W., Burnett W.T. Jr., Doherty D.G. Chemical protection against ionising radiation. Radiat. Res. 7:1957;1-12.
18. King J., LaMotte C. El mouse as a model of focal epilepsy: a review. Epilepsia. 30:1989;257-265.
19. Loscher W. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 2:1988;145-181.
20. Loscher W., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs: II. Maximal electroshock seizure models. Epilepsy Res. 8:1991;79-94.
21. Loscher W., Honack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs: III. Pentylenetetrazole seizure models. Epilepsy Res. 8:1991;171-189.
22. MacGregor D.G., Miller W.J., Stone T.W. Mediation of the neuroprotective action of R-phenylisopropyl-adenosine through a centrally located adenosine A1 receptor. Br. J. Pharmacol. 110:1993;470-476.
23. Malhotra J., Gupta Y.K. Effect of adenosine receptor modulation on pentylenetetrazole-induced seizures in rats. Br. J. Pharmacol. 120:1997;282-288.
24. Murray T.F., Sylvester D., Schultz C.S., Szot P. Purinergic modulation of the seizure threshold for pentylenetetrazol in the rat. Neuropharmacology. 24:1985;761-766.
25. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 1982;Academic Press, Sydney.
26. Phillips E., Newsholme E.A. Maximum activities, properties and distribution of 5′nucleotidase, adenosine kinase and adenosine deaminase in rat and human brain. J. Neurochem. 33:1979;553-558.
27. Pourgholami M.H., Rostampour M., Mirnajafi-Zadeh J., Palizvan M.R. Intra-amygdala infusion of 2-chloroadenosine suppresses amygdala-kindled seizures. Brain Res. 775:1997;37-42.
28. Racine R.J. Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 32:1972;281-294.
29. Schaeffer H.J., Schwender C.F. Enzyme inhibitors: 26. Bridging hydrophobic and hydrophilic regions on adenosine deaminase with some 9-(2-hydroxy-3-alkyl)adenines. J. Med. Chem. 17:1974;6-8.
30. Schultz V., Lownstein J.M. The purine nucleotide cycle. Studies of ammonia production and interconversions of adenine and hypoxanthine nucleotides and nucleosides in rat brain in situ. J. Biol. Chem. 253:1978;1938-1943.
31. Stevens D.R., Haas H.L. Purines in epilepsy. Avanzini G., Regesta G., Tanganelli P., Avoli M. Molecular and cellular targets of anti-epileptic drugs. 1997;55-57 John Libby and Company, London.
32. Van Wylen D.G., Park T.S., Rubio R., Berne R.M. Increases in cerebral interstitial fluid adenosine concentration during hypoxia, local potassium infusion, and ischaemia. J. Cereb. Blood Flow Metab. 6:1986;522-528.
33. Winn H.R., Welsh J.E., Rubio R., Berne R.M. Changes in brain adenosine during bicuculline-induced seizures in rats. Effects of hypoxia and altered systemic blood pressure. Circ. Res. 47:1980;568-577.
34. Young D., Dragunow M. Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms. Neuroscience. 58:1994;245-261.
35. Zhang G., Franklin P.H., Murray T.F. Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility. J. Pharmacol. Exp. Ther. 264:1993;1415-1424.
36. Zwillich C.W., Sutton F.D., Neff T.A., Cohn W.M., Matthay R.A., Weinberger M.M. Theophylline-induced seizures in adults. Correlation with serum concentrations. Ann. Intern. Med. 82:1975;784-787.